[go: up one dir, main page]

NO172540C - Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrrolderivater - Google Patents

Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrrolderivater

Info

Publication number
NO172540C
NO172540C NO890568A NO890568A NO172540C NO 172540 C NO172540 C NO 172540C NO 890568 A NO890568 A NO 890568A NO 890568 A NO890568 A NO 890568A NO 172540 C NO172540 C NO 172540C
Authority
NO
Norway
Prior art keywords
preparation
therapeutically active
analogy procedure
pyrrol derivatives
pyrrol
Prior art date
Application number
NO890568A
Other languages
English (en)
Other versions
NO890568L (no
NO172540B (no
NO890568D0 (no
Inventor
Peter David Davis
Christopher Huw Hill
Geoffrey Lawton
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888803048A external-priority patent/GB8803048D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO890568D0 publication Critical patent/NO890568D0/no
Publication of NO890568L publication Critical patent/NO890568L/no
Publication of NO172540B publication Critical patent/NO172540B/no
Publication of NO172540C publication Critical patent/NO172540C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044—Pyrrole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO890568A 1988-02-10 1989-02-09 Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrrolderivater NO172540C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888803048A GB8803048D0 (en) 1988-02-10 1988-02-10 Substituted pyrroles
GB888827565A GB8827565D0 (en) 1988-02-10 1988-11-25 Substituted pyrroles

Publications (4)

Publication Number Publication Date
NO890568D0 NO890568D0 (no) 1989-02-09
NO890568L NO890568L (no) 1989-08-11
NO172540B NO172540B (no) 1993-04-26
NO172540C true NO172540C (no) 1993-08-04

Family

ID=26293462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO890568A NO172540C (no) 1988-02-10 1989-02-09 Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrrolderivater

Country Status (22)

Country Link
US (1) US5057614A (no)
EP (1) EP0328026B1 (no)
JP (1) JPH0730071B2 (no)
AU (1) AU623630B2 (no)
CA (1) CA1320194C (no)
CZ (1) CZ280738B6 (no)
DE (1) DE58904168D1 (no)
DK (1) DK171891B1 (no)
DZ (1) DZ1323A1 (no)
ES (1) ES2054890T3 (no)
FI (1) FI96861C (no)
HU (1) HU201054B (no)
IE (1) IE63489B1 (no)
IL (1) IL89167A (no)
IS (1) IS1941B (no)
MC (1) MC2010A1 (no)
NO (1) NO172540C (no)
NZ (1) NZ227850A (no)
PH (1) PH25185A (no)
PT (1) PT89661B (no)
SK (1) SK278989B6 (no)
YU (1) YU47101B (no)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
PT93947B (pt) * 1989-05-05 1996-11-29 Goedecke Ag Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
JPH07504673A (ja) * 1992-03-20 1995-05-25 ザ・ウエルカム・ファウンデーション・リミテッド 抗ウイルス活性を有するインドール誘導体
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5290777A (en) * 1993-02-24 1994-03-01 Regents Of The Univ. Of California Use for topsentin compounds and pharmaceutical compositions containing same
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
TW270114B (no) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
DK0657458T3 (da) * 1993-12-07 2001-10-29 Lilly Co Eli Inhibitorer af proteinkinase-C
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
FI945705A (fi) * 1993-12-07 1996-06-03 Lilly Co Eli Bisindolyylimaleimidien parannettu synteesi
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
ES2236702T3 (es) * 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
AU2771395A (en) * 1994-06-14 1996-01-05 Sloan-Kettering Institute For Cancer Research Ceramide-activated protein kinase and methods of use of effectors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
ES2123873T3 (es) * 1994-08-04 1999-01-16 Hoffmann La Roche Pirrolocarbazol.
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
AU6836696A (en) * 1995-09-05 1997-03-27 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
US5710145A (en) * 1995-11-20 1998-01-20 Eli Lilly And Company Protein kinase C inhibitor
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
WO1997034890A1 (en) * 1996-03-20 1997-09-25 Eli Lilly And Company Synthesis of indolylmaleimides
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
EP0915698A4 (en) 1996-05-01 1999-08-11 Lilly Co Eli TREATMENT PROCEDURE FOR VEGF-RELATED DISEASES
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
PE91598A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91498A1 (es) * 1996-07-29 1998-12-22 Hoffmann La Roche Pirroles sustituidos
PE91698A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
PL331899A1 (en) * 1996-08-23 1999-08-16 Lilly Co Eli Method of obtaining bis-indolyl malimides
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
SE9603284D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
WO1998018466A2 (en) * 1996-10-31 1998-05-07 Harbor Branch Oceanographic Institution, Inc. Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
US5859261A (en) * 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
US6133452A (en) * 1997-08-22 2000-10-17 Eli Lilly And Company Synthesis of bisindolylmalimides
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
EP1057484A4 (en) * 1998-02-23 2002-11-20 Sagami Chem Res INHIBITORS OF CELL DEATH
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6225301B1 (en) 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
PL195323B1 (pl) * 1998-03-17 2007-09-28 Hoffmann La Roche Podstawione bisindolilomaleimidy do hamowania proliferacji komórek
SE9802538D0 (sv) * 1998-07-13 1998-07-13 Astra Ab New pharmaceutically active compounds
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
EP1119548B1 (en) * 1998-10-08 2004-12-08 SmithKline Beecham plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3)
US6719520B2 (en) 1998-10-08 2004-04-13 Smithkline Beecham Corporation Method and compounds
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
DK1165558T3 (da) * 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
WO2001013916A1 (fr) * 1999-08-20 2001-03-01 Sagami Chemical Research Center Medicaments inhibant la mort cellulaire
US6559164B1 (en) 1999-10-12 2003-05-06 Hoffmann-La Roche Inc. Substituted pyrroles suitable for continuous infusion
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
US6281356B1 (en) 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
GB0008264D0 (en) * 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
US6326501B1 (en) * 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US6353007B1 (en) * 2000-07-13 2002-03-05 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents
RU2003104796A (ru) * 2000-07-27 2004-08-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 3-индолил-4-фенил-1н-пиррол-2, 5-диона в качестве ингибиторов гликогенсинтазы-киназы-3 бета
US6469179B1 (en) * 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
EP1337527B1 (en) * 2000-11-07 2009-10-14 Novartis AG Indolylmaleimide derivatives as protein kinase c inhibitors
US6645970B2 (en) * 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
ES2263681T3 (es) * 2000-12-08 2006-12-16 Ortho-Mcneil Pharmaceutical, Inc. Compuestos de pirrolina indazolil-substituidos como inhibidores de la kinasa.
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US20030143185A1 (en) * 2001-10-29 2003-07-31 Shearwater Corporation Polymer conjugates of protein kinase C inhibitors
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
WO2003076442A1 (en) * 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors
KR20040091113A (ko) * 2002-03-08 2004-10-27 일라이 릴리 앤드 캄파니 피롤-2,5-디온 유도체 및 ｇｓｋ-3 억제제로서 그의 용도
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
EP1900738A3 (en) * 2002-05-08 2008-04-09 Janssen Pharmaceutica, N.V. Substituted pyrroline kinase inhibitors
CA2485527A1 (en) * 2002-05-08 2003-11-20 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
AU2003238874A1 (en) 2002-06-05 2003-12-22 Janssen Pharmaceutica N.V. Bisindolyl-maleimid derivatives as kinase inhibitors
ES2312785T3 (es) * 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
US6800655B2 (en) * 2002-08-20 2004-10-05 Sri International Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
GB0303319D0 (en) * 2003-02-13 2003-03-19 Novartis Ag Organic compounds
EP1611132A1 (en) * 2003-03-27 2006-01-04 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
CA2529353A1 (en) * 2003-06-13 2005-01-06 Janssen Pharmaceutica N.V. Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
AU2004262927B2 (en) 2003-08-08 2008-05-22 Novartis Ag Combinations comprising staurosporines
US7648989B2 (en) * 2004-01-19 2010-01-19 Novartis Ag Indolylmaleimide derivatives as PKC inhibitors
BRPI0509754A (pt) * 2004-04-08 2007-10-16 Novartis Ag inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
CA2589127C (en) * 2004-12-08 2013-02-05 Johannes Gutenberg-Universitat Mainz 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
WO2006078421A2 (en) * 2005-01-04 2006-07-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow
RU2547148C2 (ru) * 2005-02-09 2015-04-10 Аркьюл, Инк. Композиции и способы лечения рака
PL1904482T3 (pl) * 2005-07-11 2011-06-30 Novartis Ag Pochodne indolilomaleimidowe
WO2007027974A1 (en) * 2005-09-02 2007-03-08 The Board Of Trustees Of The Leland Stanford Junior University Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
JP2009508868A (ja) 2005-09-16 2009-03-05 シェーリング コーポレイション テモゾロミドおよびプロテインキナーゼインヒビターを用いる薬学的組成物および方法
CA2673368C (en) * 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
EP2392574B1 (en) * 2007-06-22 2013-12-18 ArQule, Inc. Indolyl pyrrolidines for the treatment of cancer
JP5425060B2 (ja) * 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
CN101801937A (zh) * 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
FR2927075A1 (fr) * 2008-02-04 2009-08-07 Centre Nat Rech Scient Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes
US8304421B2 (en) * 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
EP2343291A1 (en) * 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
GB201111427D0 (en) * 2011-07-05 2011-08-17 Amakem Nv Novel bisindolylmaleimides, pan-pkc inhibitors
EP2928465B1 (en) * 2012-12-10 2020-11-18 Centogene GmbH Use of maleimide derivatives for preventing and treating cancer
WO2014090398A1 (en) * 2012-12-10 2014-06-19 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
CN103382199A (zh) * 2013-06-28 2013-11-06 北京理工大学 一种n-烷基-双吲哚马来酰亚胺的制备方法
JP2017524739A (ja) 2014-07-17 2017-08-31 アンセルムＩｎｓｅｒｍ 神経筋接合部関連疾患の処置方法
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
CN105777751B (zh) * 2016-04-26 2018-12-11 浙江工业大学 一种双芳基马来酰亚胺类化合物及其药学上可接受的盐及其制备方法和应用
US20230203017A1 (en) * 2021-12-28 2023-06-29 Kamal D. Mehta Protein Kinase C Beta Inhibitors and Uses Thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS62220196A (ja) * 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
AU605304B2 (en) * 1987-06-22 1991-01-10 Nihon Tokushu Nayaku Seizo K.K. Benzo-fused cyclic compounds
PT93947B (pt) * 1989-05-05 1996-11-29 Goedecke Ag Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem

Also Published As

Publication number Publication date
NZ227850A (en) 1991-11-26
YU28489A (en) 1991-06-30
DK55889A (da) 1989-08-11
FI890652A0 (fi) 1989-02-10
YU47101B (sh) 1994-12-28
PH25185A (en) 1991-03-27
CZ280738B6 (cs) 1996-04-17
IS3433A7 (is) 1989-08-11
DZ1323A1 (fr) 2004-09-13
DK171891B1 (da) 1997-08-04
DK55889D0 (da) 1989-02-07
IS1941B (is) 2004-07-30
NO890568L (no) 1989-08-11
IE63489B1 (en) 1995-05-03
JPH01233281A (ja) 1989-09-19
PT89661B (pt) 1994-02-28
CA1320194C (en) 1993-07-13
EP0328026B1 (de) 1993-04-28
HU201054B (en) 1990-09-28
AU623630B2 (en) 1992-05-21
SK75289A3 (en) 1998-05-06
FI96861B (fi) 1996-05-31
FI96861C (fi) 1996-09-10
NO172540B (no) 1993-04-26
AU2965889A (en) 1989-08-10
DE58904168D1 (de) 1993-06-03
US5057614A (en) 1991-10-15
MC2010A1 (fr) 1990-02-16
FI890652A (fi) 1989-08-11
PT89661A (pt) 1989-10-04
NO890568D0 (no) 1989-02-09
EP0328026A1 (de) 1989-08-16
IL89167A (en) 1994-02-27
JPH0730071B2 (ja) 1995-04-05
ES2054890T3 (es) 1994-08-16
IL89167A0 (en) 1989-09-10
IE890416L (en) 1989-08-10
HUT49348A (en) 1989-09-28
SK278989B6 (sk) 1998-05-06
CZ75289A3 (en) 1995-12-13

Similar Documents

Publication Publication Date Title
NO172540C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrrolderivater
NO174101C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive triazolderivater
NO170483C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalin- og indanderivater
NO176796C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive triazolderivater
NO159089C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive glutarimidderivater.
NO171506C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive adenosin-derivater
NO170884C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrimidinderivater
NO174467C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive kromanderivater
NO176275C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridazinonderivater
NO166083C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyridazodiazepinderivater.
NO165841C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive heteroaryl-3-okso-propannitril-derivater.
NO171507C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive nukleotidderivater
NO169711C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive etylendiaminmonoamid-derivater
NO167912C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive aromatiske forbindelser
NO175429C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive 16-dehydro-vitamin-D3-derivater
NO173334C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive alkylaminoalkylenderivater 2H-1-benzopyraner
NO172489C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive imidazolderivater
NO168107C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1,4-dihydropyridiner
NO170021C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 3-propenylcefem-derivater
NO174391C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive kromanderivater
NO164020C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fenetanolaminderivater.
NO172643C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive benzopyranolderivater
NO168037C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive purin-derivater.
NO171065C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrimidinderivater
NO174422C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive kromanderivater

Legal Events

Date Code Title Description
MK1K Patent expired